Skip to main content
OpenTrials
Completed

NCT Number: NCT05068934

The Relationship Between Epicardial Fat Tissue and Cardiac Function in HFpEF Patients

Heart failure with preserved ejection fraction (HFpEF) refers to a group of symptoms and signs of heart failure, normal or near-normal left ventricular systolic function (EF>50%), and ventricular muscle diastolic dysfunction and A clinical syndrome characterized by decreased compliance and increased stiffness. The pathogenesis of HFpEF is related to impaired lipid metabolism and inflammation. Epicardial adipose tissue (Epicardial Adipose tissue, EAT) is a kind of visceral adipose tissue. Related studies have shown that extracardiac Membrane fat is related to inflammation markers, cardiometabolic risk and cardiovascular disease.However, there is still no research investigating the the relationship between epicardial fat thickness and Cardiac Function in HFpEF patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heart Failure With Preserved Ejection Fraction

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Affiliated Hospital of Chongqing Medical University

Chongqing, China

About this study

Heart failure with preserved ejection fraction (HFpEF) refers to a group of symptoms and signs of heart failure, normal or near-normal left ventricular systolic function (EF>50%), and ventricular muscle diastolic dysfunction and A clinical syndrome characterized by decreased compliance and increased stiffness. The pathogenesis of HFpEF is related to impaired lipid metabolism and inflammation. Epicardial adipose tissue (Epicardial Adipose tissue, EAT) is a kind of visceral adipose tissue, which is composed of adipose tissue deposited between the myocardium and the visceral layer of the pericardium. It is closely adjacent to the coronary arteries and myocardium. Related studies have shown that extracardiac Membrane fat is related to inflammation markers, cardiometabolic risk and cardiovascular disease.However, there is still no research investigating the the relationship between epicardial fat thickness and Cardiac Function in HFpEF patients. This study intends to observe the relationship between epicardial fat thickness and left and right functions in patients with HFpEF, and evaluate whether epicardial fat thickness can be used as an indicator of left and right dysfunction.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult aged >=18years old;
  • Diagnosed with HFpEF.

Diagnostic criteria including:

  • left ventricular ejection fraction ≥50%；
  • with the symptoms and/or signs of heart failure；
  • BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL；
  • at least one additional criterion: relevant structural heart disease(LVH and/or LAE) or diastolic dysfunction

Exclusion criteria

  • LVEF less than 45% at any time;
  • Severe liver failure;
  • Primary pulmonary hypertension;
  • Age <18 years old.

Treatment and study plan

Primary outcomes

  1. Epicardial Fat Tissue

    Time frame: On admission

    Epicardial Fat Tissue by cardiac color Doppler ultrasound

  2. Cardiac Function

    Time frame: On admission

    Left ventricular diastolic function and right ventricular systolic function by cardiac color Doppler ultrasound

  3. Composite Endpoint of Worsening Heart Failure Event and Cardiovascular Death

    Time frame: From date of discharge until the date of first worsening HF event or date of death, whichever came first, assessed up to 5 years

    Composite Endpoint of Worsening Heart Failure Event and Cardiovascular Death

Secondary outcomes

  1. Worsening HF Event

    Time frame: From date of discharge until the date of first worsening HF event or date of death, whichever came first, assessed up to 5 years

    Worsening Heart Failure Event

  2. CV Death

    Time frame: From date of discharge until the date of death, whichever came first, assessed up to 10 years

    Cardiovascular Death

  3. All-cause Death

    Time frame: From date of discharge until the date of death, whichever came first, assessed up to 10 years

    Death from any causes

Sponsors and collaborators

Lead sponsor

Dongying Zhang

Other

Registry information

Official study title

The Relationship Between Epicardial Fat Tissue and Cardiac Function in HFpEF

Important dates

Study start
2020
Primary completion
2025
Study completion
2025
First posted
Oct 6, 2021
Registry last updated
Jan 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.